Advanced Search

 

Study ID Status Title Patient Level Data
FAP10001 Completed Dose proportionality of fluticasone propionate from HFA inhalers and effect of propellant on FP pharmacokinetics Study Listed on ClinicalStudyDataRequest.com
FAP10006 Completed A Randomized, Open-Label, 2-Way Crossover, Repeat-Dose Study in Pediatric Subjects with Asthma, Age 4-11 Years, to Compare Systemic Exposure of Fluticasone Propionate 2x44mcg Following Administration by Metered-Dose Inhalers Containing Hydrofluoroalkane or Chlorofluorocarbon Propellants Study Listed on ClinicalStudyDataRequest.com
FAP19052 Completed Pharmacodynamics of the 88mcg BID dose of the Hydrofluoroalkane propellant formulation of inhaled Fluticasone Propionate following Administration via the Metered-dose Inhaler in Pediatric Subjects 4 to 11 years of age with Asthma Study Listed on ClinicalStudyDataRequest.com
FAP19058 Completed Systemic exposure of the fluticasone propionate from the hydrofluoroalkane propellant formulation via the metered-dose inhaler with and without a spacer in pediatric subjects 4 to 11 years of age with asthma. Study Listed on ClinicalStudyDataRequest.com
FAP30001 Completed A Randomized, Double-Blind, Parallel-Group Trial of Inhaled Fluticasone Propionate/GR106642X 220mcg BID and 440mcg BID in Adolescent and Adult Subjects with Asthma
FAP30007 Completed A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 12-Week Trial of Inhaled Fluticasone Propionate 88mcg BID, 220mcg BID, and 440mcg BID versus Placebo in Propellant GR106642X in Adolescent and Adult Subjects with Asthma who are Maintained on Inhaled Corticosteroid Therapy Study Listed on ClinicalStudyDataRequest.com
FAP30008 Completed A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 12-Week Trial of Inhaled Fluticasone Propionate 88mcg BID, 220mcg BID, and 440mcg BID versus Placebo in Propellant GR106642X in Adolescent and Adult Subjects with Asthma who are Maintained on Bronchodilator Therapy Study Listed on ClinicalStudyDataRequest.com
FAP30010 Completed A Randomized, Double-Blind, Paralled-Group, Placebo-Controlled 12 Week Trial of Inhaled Fluticasone Propionate 88mcg Twice Daily versus Placebo in Propellant GR106642X in Pediatric Subjects 4 to 11 years of age with Asthma Study Listed on ClinicalStudyDataRequest.com
FAP30011 Completed A multi-centre, randomised, double-blind, parallel group clinical trial to assess the efficacy and safety of fluticasone propionate/GR106642X 250mg BD compared with fluticasone propionate/propellants CFC 250mg BD administered by pressurised metered-dose inhaler in adult Chinese patients with asthma.
FAS10002 Completed A multiple-dose, open-label, 2-way crossover study in pediatric subjects with asthma aged 1 to < 4 years to compare the systemic exposure of fluticasone propionate 88mcg administered via the hydrofluoroalkane metered-dose inhaler using the valved holding chambers, Aerochamber Plus™ and Babyhaler™, with face-masks Study Listed on ClinicalStudyDataRequest.com
FAS106533 Completed PD of Hydrofluoroalkane propellant of inhaled fluticasone propionate following administration in pediatric subjects 6-12 months of age with asthma Study Listed on ClinicalStudyDataRequest.com
FAS30006 Completed A Multicentre, Randomised, Double-Blind, Parallel Group Clinical Trial to Compare the Efficacy and Safety of Fluticasone propionate (FP) 200mg/day with Fluticasone propionate 400mg/day Administered for 52 Weeks via a Multidose Powder Device (Diskus) to Paediatric patients with Asthma.
FAS30007 Completed A multicentre, randomised, double-blind, parallel group placebo-controlled study to determine the efficacy and safety of fluticasone propionate 200mcg/day delivered via the Babyhaler in paediatric subjects aged 12 to 47 months with recurrent/persistent asthma like symptoms. Study Listed on ClinicalStudyDataRequest.com
FAS30009 Completed A multicentre, randomised, parallel-group open label study to assess the long term safety of fluticasone propionate 100mcg bd via the MDI and babyhaler spacer device, compared with sodium cromoglycate 5mg QDS in children aged 12-47months with documented evidence of recurrent/persistent asthma-like symptoms. Study Listed on ClinicalStudyDataRequest.com
FAS30030 Completed A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Safety and Efficacy Study of Fluticasone Propionate 88mcg BID Versus Placebo BID delivered via HFA MDI and a valved holding chamber with facemask in Pediatric Subjects with Asthma age 12 months to 47 months. Study Listed on ClinicalStudyDataRequest.com
FAS40008 Completed An interventional three year study for asthma control - In what way and in what kind of population is it possible to get asthmatic patients free from symptoms, keep the patients in work, restore a normal lung function, diminish hyperreactivity and normalise quality of life? Study Listed on ClinicalStudyDataRequest.com
FAS40008_1 Completed An interventional three year study for asthma control - In what way and in what kind of population is it possible toget asthmatic patients free from symptoms, keep the patients in work, restore a normal lung function, diminish hyperreactivity and normalise quality of life?
FAS40009 Completed The therapeutic ratio of inhaled corticosteroids in adult asthma: A dose-range comparison between fluticasone propionate and budesonide measuring their effect on bronchial hyperresponsiveness and adrenal cortex function.
FAS40012 Completed Early Intervention with Inhaled Corticosteroids in Wheezing Pre-school Children: A Single-Centre, Double-Blind, Randomised 5 Years Parallel-Group Study Comparing Adjusted Dosing of Inhaled Fluticasone Propionate With Inhaled Placebo Both Administered by Metered Dose Inhaler via a Babyhaler. Study Listed on ClinicalStudyDataRequest.com
FAS40017 Completed A double blind, randomised, parallel group study with Flixotide Diskus (250microg) bd and Pulmicort Turbohaler (400microg) bd to compare lowest effective maintenance doses followed by an open health economic evaluation.
FAS40019 Completed A single centre study, randomised, double blind, double-dummy crossover study to determine if the total lung deposition of FP is affected by delivery system (pMDI with Babyhaler or Volumatic compared with the Diskus inhaler), in children aged between 4-6 years and 12-15 years old with asthma.
FBX104114 Completed A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects with Hepatic Fibrosis who Have Failed Prior Antiviral Therapy
FCO30002 Completed A double/blind, randomised, controlled, three parallel group, multicenter study to compare the acute effects of inhaled Flixotide/Salmeterol vs. Decortin/Flixotide/Salmeterol vs. Salmeterol in patients with COPD
FCO40004 Completed Self-management of COPD, including self-treatment of exacerbations in an outpatient population.
FFA10001 Completed A randomised, double-blind, placebo-controlled, dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single inhaled doses of GW685698X in healthy male subjects Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.